Journal article
External validation and comparison of four cardiovascular risk prediction models with data from the Australian Diabetes, Obesity and Lifestyle study
L Albarqouni, JA Doust, D Magliano, ELM Barr, JE Shaw, PP Glasziou
Medical Journal of Australia | WILEY | Published : 2019
DOI: 10.5694/mja2.12061
Abstract
Objectives: To evaluate the performance of the 2013 Pooled Cohort Risk Equation (PCE-ASCVD) for predicting cardiovascular disease (CVD) in an Australian population; to compare this performance with that of three frequently used Framingham-based CVD risk prediction models. Design: Prospective national population-based cohort study. Setting: 42 randomly selected urban and non-urban areas in six Australian states and the Northern Territory. Participants: 5453 adults aged 40–74 years enrolled in the Australian Diabetes, Obesity and Lifestyle study and followed until November 2011. We excluded participants who had CVD at baseline or for whom data required for risk model calculations were missing...
View full abstractGrants
Awarded by Heart Foundation
Funding Acknowledgements
The AusDiab study was coordinated by the Baker Heart and Diabetes Institute, and we gratefully acknowledge the support and assistance of the AusDiab Steering Committee and the study participants. The AusDiab study was funded by the National Health and Medical Research Council (grants 233200 and 1007544), the Australian Government Department of Health and Ageing, the Northern Territory Department of Health and Community Services, the Tasmanian Department of Health and Human Services, the New South Wales, Western Australian, and South Australian Departments of Health, the Victorian Department of Human Services, Queensland Health, City Health Centre Diabetes Service (Canberra), Diabetes Australia, Diabetes Australia Northern Territory, the estate of the late Edward Wilson, the Jack Brockhoff Foundation, Kidney Health Australia, the Marian and FH Flack Trust, the Menzies Research Institute, the Pratt Foundation, Royal Prince Alfred Hospital (Sydney), the Victorian Government OIS Program, Abbott Australasia, Alphapharm, Amgen Australia, AstraZeneca, Bristol-Myers Squibb, Eli Lilly Australia, GlaxoSmithKline, Janssen-Cilag, Merck Sharp & Dohme, Novartis Pharmaceuticals, Novo Nordisk Pharmaceuticals, Pfizer, Roche Diagnostics Australia, Sanofi Aventis, and Sanofi-Synthelabo. Elizabeth Barr is supported by a Heart Foundation post-doctoral fellowship (101291).